马罗尼生物...   MBII

-- -- --

From January 1, 2022 to March 31, 2022 Settlement of restricted stock units

From December 31, 2020 to December 31, 2021 Net settlement of options Employee stock purchase plan Settlement of restricted stock units Issuance and settlement of restricted stock units in lieu of bonus payments, net Exercise of warrants Issuance of common stock in settlement of contingent consideration

From June 30, 2021 to September 30, 2021 Net settlement of options Settlement of restricted stock units Issuance and settlement of restricted stock units in lieu of bonus payments

From March 31, 2021 to June 30, 2021 Net settlement of options Settlement of restricted stock units Employee stock purchase plan Issuance and settlement of restricted stock units in lieu of bonus payments Issuance of common stock in settlement of contingent consideration

From January 1, 2021 To March 31, 2021 Net settlement of options Settlement of restricted stock units Exercise of warrants

from December 31, 2019 to December 31, 2020 Net settlement of options Employee stock purchase plan Settlement of restricted stock units Exercise of warrants

From June 30, 2020 to September 30, 2020 Net settlement of options Issuance of common stock in connection with exercise of warrants Settlement of restricted stock units

From March 31, 2020 to June 30, 2020 Exercise of options Settlement of restricted stock units Employee stock purchase plan Exercise of warrants

From December 31, 2019 to March 31, 2020 Net settlement of options Issuance of common stock in connection with call to exercise warrants

from December 31, 2018 to December 31, 2019 Net settlement of options Employee stock purchase plan Settlement of restricted stock units Issuance of common stock in connection with call to exercise warrants Issuance of common stock in connection with Pro Farm acquisition.

from June 30, 2019 to September 30, 2019 Net settlement of options Issuance of common stock in connection with call to exercise warrants Issuance of common stock in connection with Pro Farm acquisition

from March 31, 2019 to June 30,2019 Net settlement of options

from December 31, 2017 to December 31, 2018 Net settlement of options Exercise of warrants Settlement of restricted stock units Conversion of related party notes for common stock and warrants Conversion of secured promissory notes for common stock and warrants Conversion of convertible notes for common stock and warrants Fair value of common stock and warrants issued to placement agent in connection with private placement and note conversion Issuance of common stock and warrants in private placement, net of offering costs and underwriter commissions Issuance of common stock in follow-on offering, net of offering costs and underwriter commissions

On December 15, 2017, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein, including Ospraie Ag Science LLC (“Ospraie”). On February 5, 2018, pursuant to the Purchase Agreement, the Company issued to these investors, an aggregate of 40,000,001 units, with each unit purchased consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock, and each unit purchased by the investors consisting of one share of common stock and one warrant to purchase 0.8 shares of Common Stock, for an aggregate purchase price of $30,000,000, including the conversion to units of all aggregate principal amounts outstanding under the Purchase Agreement. Also on February 5, 2018, the Company converted, pursuant to an amendment, dated December 15, 2017, to the October 2012 and April 2013 Secured Promissory Notes, $10,000,000 aggregate principal amount of indebtedness outstanding under the October 2012 and April 2013 Secured Promissory Notes to an aggregate of 5,714,285 shares of common stock and warrants to purchase 1,142,856 shares of common stock (such conversion, the “Snyder Debt Conversion”), such that $2,450,000 of principal under the October 2012 and April 2013 Secured Promissory Notes now remains outstanding. In addition, in connection with its role as exclusive placement agent and financial adviser with respect to the transactions contemplated by the Purchase Agreement, National Securities Corporation (the “Placement Agent”) received warrants to purchase 2,017,143 shares of Common Stock, as well as 800,000 shares of Common Stock.

from December 31, 2016 to December 31, 2017 Exercise of stock options Issuance of common stock in follow-on offering, net of offering costs and underwriter commissions

from December 31, 2015 to December 31, 2016 Exercise of stock options Conversion of restricted stock units

from December 31, 2014 to December 31, 2015 Exercise of stock options Conversion of restricted stock units

from December 31, 2013 to December 31, 2014 Exercise of stock options Cash exercise of common stock warrants Issuance of common stock in follow-on offering, net of offering costs and underwriter commission

from December 31, 2012 to December 31, 2013 Conversion of preferred stock into common stock Cash exercise of preferred stock warrants Exercise of stock options Net exercise of preferred stock warrants Convertible notes converted into common stock Cash exercise of common stock warrants Net exercise of common stock warrants Issuance of common stock upon initial public offering, net of offering costs and underwriter commission On August 1, 2013, the Company amended and restated its certificate of incorporation to effect a reverse split of shares of its common stock at a 1-for-3.138458 ratio

from December 31, 2012 to September 30, 2013 Conversion of preferred stock into common stock Cash exercise of preferred stock warrants Exercise of stock options Net exercise of preferred stock warrants Convertible notes converted into common stock Cash exercise of common stock warrants Net exercise of common stock warrants Issuance of common stock upon initial public offering, net of offering costs and underwriter commission On August 1, 2013, the Company amended and restated its certificate of incorporation to effect a reverse split of shares of its common stock at a 1-for-3.138458 ratio

Upon the closing of the IPO, all shares of the Company’s outstanding convertible preferred stock and convertible notes automatically converted into shares of common stock and outstanding warrants to purchase convertible preferred stock and certain warrants to purchase common stock were exercised into shares of common stock.

a 1-for-3.138458 reverse stock split;the automatic conversion into an aggregate of 8,513,473 shares of common stock of all outstanding shares of our preferred stock, including shares of Series B convertible preferred stock issued upon the full exercise of warrants outstanding as of March 31, 2013;the issuance of 70,679 shares of common stock, based on the initial public offering price, at the completion of this offering, upon the net exercise of all outstanding warrants to purchase shares of Series A and Series C convertible preferred stock, which have been exercised effective upon the completion of this offering;the issuance of 40,172 shares of common stock, based on the initial public offering price, at the completion of this offering, upon the net exercise of outstanding warrants to purchase common stock that will be automatically exercised upon the completion of this offering in accordance with their terms;the issuance of 3,624,250 shares of common stock, based on the initial public offering price, at the completion of this offering, upon the conversion of all outstanding convertible notes, including principal and interest, to the extent accrued as of March 31, 2013, that will be automatically converted upon the completion of this offering in accordance with their terms.

On August 1, 2013, the Company’s board of directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect the conversion of its outstanding convertible preferred stock into common stock on a 1-for-1 basis followed immediately by a reverse split of shares of its common stock (including the common stock issued upon conversion of the convertible preferred stock) at a 1-for-3.138458 ratio (the “Reverse Stock Split”).

On August 1, 2013, the Company amended and restated its certificate of incorporation to effect the conversion of its outstanding convertible preferred stock into common stock on a 1-for-1 basis followed immediately by a reverse split of shares of its common stock (including the common stock issued upon conversion of the convertible preferred stock) at a 1-for-3.138458 ratio (the “Reverse Stock Split”). The amendment also increased the number of shares of common stock authorized for issuance to 250,000,000 shares. The par value of the common stock was not adjusted as a result of the Reverse Stock Split.